상세 정보

underline
Metadata Downloads : dc(xml) or Excel
Cited 0 time in scopus ci

Title 

Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug

Authors 

Y W KimY K KimJ Y LeeKyu Tae ChangH J LeeD K KimY Y Sheen

Publisher 

Informa Healthcare

Issue Date 

2008

Citation 

Xenobiotica, vol. 38, no. 3, pp. 325-339

Keywords 

3-((5-(6-Methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl) benzamide (IN-1130)activin receptor-like kinase-5 (ALK5) inhibitordistributionmetabolitepharmacokinetics3 [[4 (2 hydroxyquinoxalin 6 yl) 5 (6 methylpyridin 2 yl) 1h imidazol 2 yl]methyl]benzamide3 [[4 (3 hydroxyquinoxalin 6 yl) 5 (6 methylpyridin 2 yl) 1h imidazol 2 yl]methyl]benzamide3 [[5 (6 methylpyridin 2 yl) 4 (quinoxalin 6 yl) 1h imidazol 2 yl]methyl]benzamideantifibrotic agentdrug metabolite

Abstract 

The authors investigated the pharmacokinetics and metabolism of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl) benzamide (IN-1130), a novel ALK5 inhibitor, which suppresses renal and hepatic fibrosis, and also exerts anti-metastatic effects on breast cancer-bearing MMTV-cNeu mice model. Plasma half-lives of orally administered IN-1130 were 62.6 min in mice, 76.6 ± 10.6 min in dogs, 156.1 ± 19.3 min in rats, and 159.9 ± 59.9 min in monkeys. IN-1130 showed a high apparent permeability coefficient (Papp) of (45.0 ± 2.3) × 10-6 cm s-1 in in vitro permeability tests in a Caco-2 cell monolayer model. The bioavailability of orally administered IN-1130 was 84.9% in dogs and 34.4% in monkeys (oral dose, 5.5 mg kg-1), 11.4% in rats and 8.95% in mice (oral dose, 50.3 mg kg-1), respectively. Orally given IN-1130 was readily distributed into liver, kidneys and lungs. The major metabolite of IN-1130 (M1) was detected in the systemic circulation of rat and mouse and was purified and tentatively identified as 3-((4-(3-hydroxyquinoxaline-6-yl)-5-(6-methylpyridine-2-yl)-1H-imidazol-2-yl) methyl)benzamide or 3-((4-(2-hydroxyquinoxalin-6-yl)-5-(6-methylpyridine-2-yl)- 1H-imidazol-2-yl)methyl)benzamide. The highest levels of M1 were found in liver. The results of this study suggest that IN-1130 has the potential to serve as an effective oral anti-fibrotic drug.

ISSN 

0049-8254

Link 

http://dx.doi.org/10.1080/00498250701781924

Appears in Collections

1. Journal Articles > Journal Articles

Registered Date

2017-04-19


There are no files associated with this item.
qrcode

FusionCharts.
DSpace Software Coptright(c) 2010 MIT and Hewleft-Packard  /  KRIBB-REPOSITORY ( Email:jakim@kribb.re.kr)